A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Clinical trial NCT06057610 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06057610
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-16
- Primary completion
- 2027-10-01
- Enrollment
- 868
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.